PL3447070T3 - Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w - Google Patents

Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w

Info

Publication number: PL3447070T3
Authority: PL; Poland
Prior art keywords: papelocote; myelinization; herv; blocked; protein
Prior art date: 2012-10-02

Application number

PL18198309T

Other languages

English (en)

Inventor

Hervé Perron

Reza FIROUZI

Patrick KÜRY

Raphaël FAUCARD

Alexandra MADEIRA

Julie Joanou

Original Assignee

Geneuro Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-02

Filing date

2013-10-01

Publication date

2021-09-06

2013-10-01 Application filed by Geneuro Sa filed Critical Geneuro Sa

2021-09-06 Publication of PL3447070T3 publication Critical patent/PL3447070T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Psychiatry (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Oncology (AREA)
Management, Administration, Business Operations System, And Electronic Commerce (AREA)

PL18198309T 2012-10-02 2013-10-01 Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w PL3447070T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261708779P	2012-10-02	2012-10-02
US201261746792P	2012-12-28	2012-12-28
EP18198309.9A EP3447070B9 (en)	2012-10-02	2013-10-01	Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
PCT/EP2013/070452 WO2014053489A1 (en)	2012-10-02	2013-10-01	Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
EP13770926.7A EP2904009B1 (en)	2012-10-02	2013-10-01	Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein

Publications (1)

Publication Number	Publication Date
PL3447070T3 true PL3447070T3 (pl)	2021-09-06

Family

ID=49274655

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13770926T PL2904009T3 (pl)	2012-10-02	2013-10-01	Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w
PL18198309T PL3447070T3 (pl)	2012-10-02	2013-10-01	Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL13770926T PL2904009T3 (pl)	2012-10-02	2013-10-01	Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w

Country Status (31)

Country	Link
US (2)	US9840550B2 (pl)
EP (2)	EP3447070B9 (pl)
JP (2)	JP6379331B2 (pl)
KR (1)	KR102098033B1 (pl)
CN (2)	CN105709224B (pl)
AU (2)	AU2013326552B2 (pl)
BR (1)	BR112015007150A8 (pl)
CA (1)	CA2882781C (pl)
CY (2)	CY1121237T1 (pl)
DK (2)	DK3447070T3 (pl)
EA (2)	EA037253B1 (pl)
EC (1)	ECSP15014925A (pl)
ES (2)	ES2710748T3 (pl)
HR (2)	HRP20190274T1 (pl)
HU (2)	HUE043419T2 (pl)
IL (3)	IL237474A0 (pl)
IN (1)	IN2015DN02397A (pl)
LT (2)	LT2904009T (pl)
MX (2)	MX366846B (pl)
MY (1)	MY172209A (pl)
PL (2)	PL2904009T3 (pl)
PT (2)	PT2904009T (pl)
RS (2)	RS58320B1 (pl)
RU (1)	RU2636355C2 (pl)
SA (1)	SA515360207B1 (pl)
SG (1)	SG11201501274VA (pl)
SI (2)	SI3447070T1 (pl)
SM (1)	SMT201900087T1 (pl)
UA (1)	UA119032C2 (pl)
WO (1)	WO2014053489A1 (pl)
ZA (1)	ZA201501491B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2949342A1 (en) *	2014-05-28	2015-12-02	Geneuro SA	Antiretroviral drug targeting human endogenous retrovirus
EP3351265A1 (en) *	2017-01-20	2018-07-25	Geneuro SA	Anti-herv-k envelope antibody and uses thereof
JP7122002B2 (ja)	2017-03-01	2022-08-19	国立大学法人北海道大学	疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
US20210405011A1 (en) *	2018-09-01	2021-12-30	National University Corporation Hokkaido University	Pharmaceutical for preventing and/or treating stress load-related disease
US20220332799A1 (en) *	2019-09-04	2022-10-20	Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne)	Herv inhibitors for use in treating tauopathies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2753098B1 (fr) *	1996-09-06	1998-11-27	Sod Conseils Rech Applic	Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
EP1265989A2 (en) *	2000-03-21	2002-12-18	MS Research A/S	An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
CA2433877C (en) *	2001-01-17	2014-11-18	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
FR2865403B1 (fr) *	2004-01-23	2009-06-12	Biomerieux Sa	Composition pour le traitement d'une pathologie associee a la msrv/herv-w
US20090233888A1 (en) *	2005-03-23	2009-09-17	Usc Stevens, University Of Southern California	Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
US8410115B2 (en) *	2006-02-28	2013-04-02	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
EP2139467B1 (en) *	2007-02-08	2016-09-21	Biogen MA Inc.	Neuroprotection in demyelinating diseases
WO2009062926A1 (en) *	2007-11-12	2009-05-22	Ares Trading S.A.	Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
SMT201700366T1 (it) *	2008-07-08	2017-09-07	Geneuro Sa	Uso terapeutico di ligando specifico in malattie associate a msrv
WO2010045265A1 (en) *	2008-10-13	2010-04-22	Biovista, Inc.	Compositions and methods for treating multiple sclerosis
WO2010148323A2 (en) *	2009-06-18	2010-12-23	Whittemore Peterson Institute For Neuro-Immune Disease	Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
HUE025878T2 (en) *	2010-02-12	2016-05-30	Biogen Ma Inc	Neuroprotection in demyelinating diseases

2013
- 2013-01-10 UA UAA201504292A patent/UA119032C2/uk unknown
- 2013-10-01 KR KR1020157011152A patent/KR102098033B1/ko not_active Expired - Fee Related
- 2013-10-01 RS RS20190185A patent/RS58320B1/sr unknown
- 2013-10-01 JP JP2015533633A patent/JP6379331B2/ja active Active
- 2013-10-01 HR HRP20190274TT patent/HRP20190274T1/hr unknown
- 2013-10-01 IN IN2397DEN2015 patent/IN2015DN02397A/en unknown
- 2013-10-01 EA EA201791525A patent/EA037253B1/ru unknown
- 2013-10-01 CN CN201610152679.5A patent/CN105709224B/zh not_active Expired - Fee Related
- 2013-10-01 EP EP18198309.9A patent/EP3447070B9/en active Active
- 2013-10-01 DK DK18198309.9T patent/DK3447070T3/da active
- 2013-10-01 EA EA201590678A patent/EA028245B1/ru unknown
- 2013-10-01 MX MX2015003572A patent/MX366846B/es active IP Right Grant
- 2013-10-01 MX MX2019008916A patent/MX385003B/es unknown
- 2013-10-01 WO PCT/EP2013/070452 patent/WO2014053489A1/en not_active Ceased
- 2013-10-01 ES ES13770926T patent/ES2710748T3/es active Active
- 2013-10-01 ES ES18198309T patent/ES2878248T3/es active Active
- 2013-10-01 AU AU2013326552A patent/AU2013326552B2/en not_active Ceased
- 2013-10-01 BR BR112015007150A patent/BR112015007150A8/pt not_active Application Discontinuation
- 2013-10-01 PT PT13770926T patent/PT2904009T/pt unknown
- 2013-10-01 RS RS20210555A patent/RS61794B1/sr unknown
- 2013-10-01 HU HUE13770926A patent/HUE043419T2/hu unknown
- 2013-10-01 RU RU2015116149A patent/RU2636355C2/ru active
- 2013-10-01 US US14/429,199 patent/US9840550B2/en not_active Expired - Fee Related
- 2013-10-01 DK DK13770926.7T patent/DK2904009T3/en active
- 2013-10-01 CA CA2882781A patent/CA2882781C/en active Active
- 2013-10-01 CN CN201380051713.4A patent/CN104684927B/zh not_active Expired - Fee Related
- 2013-10-01 PL PL13770926T patent/PL2904009T3/pl unknown
- 2013-10-01 PT PT181983099T patent/PT3447070T/pt unknown
- 2013-10-01 EP EP13770926.7A patent/EP2904009B1/en active Active
- 2013-10-01 LT LTEP13770926.7T patent/LT2904009T/lt unknown
- 2013-10-01 PL PL18198309T patent/PL3447070T3/pl unknown
- 2013-10-01 LT LTEP18198309.9T patent/LT3447070T/lt unknown
- 2013-10-01 MY MYPI2015700643A patent/MY172209A/en unknown
- 2013-10-01 HU HUE18198309A patent/HUE054051T2/hu unknown
- 2013-10-01 SI SI201331879T patent/SI3447070T1/sl unknown
- 2013-10-01 SG SG11201501274VA patent/SG11201501274VA/en unknown
- 2013-10-01 SI SI201331348T patent/SI2904009T1/sl unknown
- 2013-10-01 SM SM20190087T patent/SMT201900087T1/it unknown
2015
- 2015-02-26 IL IL237474A patent/IL237474A0/en unknown
- 2015-03-04 ZA ZA2015/01491A patent/ZA201501491B/en unknown
- 2015-03-30 SA SA515360207A patent/SA515360207B1/ar unknown
- 2015-04-17 EC ECIEPI201514925A patent/ECSP15014925A/es unknown
2017
- 2017-11-07 JP JP2017214696A patent/JP6538138B2/ja not_active Expired - Fee Related
- 2017-11-14 US US15/812,745 patent/US10752675B2/en active Active
2018
- 2018-08-17 AU AU2018217328A patent/AU2018217328B2/en not_active Ceased
2019
- 2019-01-21 IL IL264382A patent/IL264382B/en active IP Right Grant
- 2019-02-07 CY CY20191100169T patent/CY1121237T1/el unknown
2020
- 2020-04-19 IL IL274047A patent/IL274047B/en active IP Right Grant
2021
- 2021-05-11 CY CY20211100400T patent/CY1124378T1/el unknown
- 2021-05-14 HR HRP20210779TT patent/HRP20210779T1/hr unknown

Also Published As

Publication number	Publication date
EA201791525A3 (ru)	2018-12-28
HK1221399A1 (zh)	2017-06-02
CN104684927A (zh)	2015-06-03
CN104684927B (zh)	2018-06-19
US20150218256A1 (en)	2015-08-06
IL274047A (en)	2020-06-30
UA119032C2 (uk)	2019-04-25
KR102098033B1 (ko)	2020-04-08
MX385003B (es)	2025-03-14
US20180066040A1 (en)	2018-03-08
ZA201501491B (en)	2016-01-27
SMT201900087T1 (it)	2019-02-28
CY1121237T1 (el)	2020-05-29
HUE054051T2 (hu)	2021-08-30
IL274047B (en)	2020-11-30
SG11201501274VA (en)	2015-05-28
EP2904009A1 (en)	2015-08-12
EP2904009B1 (en)	2018-11-21
PT3447070T (pt)	2021-05-19
CY1124378T1 (el)	2022-07-22
HUE043419T2 (hu)	2019-08-28
PL2904009T3 (pl)	2019-06-28
JP2018065814A (ja)	2018-04-26
EA037253B1 (ru)	2021-02-26
LT3447070T (lt)	2021-06-10
IL264382A (en)	2019-02-28
SI2904009T1 (sl)	2019-04-30
JP2016500651A (ja)	2016-01-14
KR20150064147A (ko)	2015-06-10
EP3447070B1 (en)	2021-02-24
EP3447070A1 (en)	2019-02-27
ES2878248T3 (es)	2021-11-18
CN105709224B (zh)	2020-06-05
AU2018217328A1 (en)	2018-09-06
BR112015007150A8 (pt)	2018-02-06
SA515360207B1 (ar)	2018-09-18
PT2904009T (pt)	2019-02-19
LT2904009T (lt)	2019-03-12
DK3447070T3 (da)	2021-05-10
MX366846B (es)	2019-07-26
RU2636355C2 (ru)	2017-11-22
CA2882781C (en)	2021-06-15
CN105709224A (zh)	2016-06-29
HRP20210779T1 (hr)	2021-09-17
EA201590678A1 (ru)	2015-07-30
JP6379331B2 (ja)	2018-08-29
RS58320B1 (sr)	2019-03-29
IL264382B (en)	2020-05-31
RS61794B1 (sr)	2021-06-30
US9840550B2 (en)	2017-12-12
ECSP15014925A (es)	2017-07-31
MX2015003572A (es)	2015-08-20
AU2013326552B2 (en)	2018-05-24
CA2882781A1 (en)	2014-04-10
DK2904009T3 (en)	2019-03-11
AU2018217328B2 (en)	2019-09-19
MY172209A (en)	2019-11-15
EP3447070B9 (en)	2021-08-11
JP6538138B2 (ja)	2019-07-03
EA028245B1 (ru)	2017-10-31
WO2014053489A1 (en)	2014-04-10
RU2015116149A (ru)	2016-11-27
EA201791525A2 (ru)	2018-07-31
BR112015007150A2 (pt)	2017-07-04
ES2710748T3 (es)	2019-04-26
HRP20190274T1 (hr)	2019-04-05
IN2015DN02397A (pl)	2015-09-04
IL237474A0 (en)	2015-04-30
SI3447070T1 (sl)	2021-08-31
MX2019008916A (es)	2019-11-11
US10752675B2 (en)	2020-08-25
AU2013326552A1 (en)	2015-03-05

Publication	Publication Date	Title
LTPA2020510I1 (lt)	2020-07-10	Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
HUE043171T2 (hu)	2019-08-28	Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
IL235512B (en)	2018-06-28	Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
PL2717692T3 (pl)	2020-06-15	Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
EP2906208A4 (en)	2016-06-08	THERAPEUTIC TREATMENT
PL2768493T3 (pl)	2020-03-31	Fitokannabinoidy do stosowania w leczeniu raka piersi
LT2885010T (lt)	2020-04-27	Tautopatijos gydymo būdai
EP2723384A4 (en)	2015-08-12	TREATMENT OF PROTEINOPATHIES
HRP20182069T1 (hr)	2019-02-08	Farmaceutski pripravci za liječenje alzheimerove bolesti
HUE048876T2 (hu)	2020-08-28	Rákos megbetegedések kezelése
PL2739153T3 (pl)	2019-04-30	Leczenie raka sutka
HUE053247T2 (hu)	2021-06-28	Mieloszuppresszió kezelése
PL2928905T3 (pl)	2019-05-31	Sposób oczyszczania białek terapeutycznych
HUE053565T2 (hu)	2021-07-28	Adagolási rendek Pompe betegség kezelésére
EP2830633A4 (en)	2015-08-26	COMBINATION THERAPY FOR CANCER TREATMENT
EP2750709A4 (en)	2015-06-10	TREATMENT OF KACHEXIE
PL2718434T3 (pl)	2018-08-31	Kompozycje i sposoby leczenia choroby trzewnej
EP2821053A4 (en)	2015-12-02	CLEANSING COMPOSITION FOR THE SKIN
IL234606B (en)	2021-04-29	Novel methods and composition for treatment of disease
LTPA2020511I1 (lt)	2020-07-27	Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
LT2958624T (lt)	2021-08-10	Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
IL229081A0 (en)	2013-12-31	Isoxazolines as therapeutic agents
HRP20181000T1 (hr)	2018-09-21	Postupci liječenja stanja povezanih s kosom
PL3447070T3 (pl)	2021-09-06	Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w